HRP20090550T1 - UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA - Google Patents
UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA Download PDFInfo
- Publication number
- HRP20090550T1 HRP20090550T1 HR20090550T HRP20090550T HRP20090550T1 HR P20090550 T1 HRP20090550 T1 HR P20090550T1 HR 20090550 T HR20090550 T HR 20090550T HR P20090550 T HRP20090550 T HR P20090550T HR P20090550 T1 HRP20090550 T1 HR P20090550T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- epa
- dha
- drug
- ethyl ester
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract 7
- 239000000203 mixture Substances 0.000 title abstract 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 title 1
- 125000004494 ethyl ester group Chemical group 0.000 claims abstract 14
- 239000003814 drug Substances 0.000 claims abstract 12
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 claims abstract 5
- 201000000980 schizophrenia Diseases 0.000 claims abstract 5
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims abstract 4
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 4
- 208000020016 psychiatric disease Diseases 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 3
- 150000007513 acids Chemical class 0.000 claims abstract 3
- 208000028683 bipolar I disease Diseases 0.000 claims abstract 3
- 208000024714 major depressive disease Diseases 0.000 claims abstract 3
- 208000011580 syndromic disease Diseases 0.000 claims abstract 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 2
- 229930195729 fatty acid Natural products 0.000 claims abstract 2
- 239000000194 fatty acid Substances 0.000 claims abstract 2
- 150000004665 fatty acids Chemical class 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims 11
- 150000004671 saturated fatty acids Chemical class 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037424 autonomic function Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Upotreba pripravka koji sadrži u koncentraciji izraženoj kao %, težinski, ukupne težine masnih kiselina u pripravku, biloa) etilni ester DHA je 34, a etilni ester EPA je 40, gdje etilni esteri EPA + DHA su 85, ilib) etilni ester DHA je 30, a etilni ester EPA je 44, gdje etilni esteri EPA + DHA su 80, a etilni esteri drugih (C20, C21, C22) n-3 kiselina su 3, ilic) etilni ester DHA je 34, a etilni ester EPA je 40, gdje etilni esteri EPA + DHA su 80, a ukupni etilni esteri n-3 kiselina su 90, ilid) etilni ester DHA je 80, a etilni ester EPA je 85, u pripravi lijeka za sprječavanje i/ili liječenje psihijatrijskih poremećaja središnjeg živčanog sustava (CNS), koje se bira između shizofrenije, manično-depresivnog sindroma, velike depresije, te Alzheimerove bolesti. Patent sadrži još 13 patentnih zahtjeva.
Claims (14)
1. Upotreba pripravka koji sadrži u koncentraciji izraženoj kao %, težinski, ukupne težine masnih kiselina u pripravku, bilo
a) etilni ester DHA je >34, a etilni ester EPA je >40, gdje etilni esteri EPA + DHA su >85, ili
b) etilni ester DHA je >30, a etilni ester EPA je >44, gdje etilni esteri EPA + DHA su >80, a etilni esteri drugih (C20, C21, C22) n-3 kiselina su >3, ili
c) etilni ester DHA je >34, a etilni ester EPA je >40, gdje etilni esteri EPA + DHA su >80, a ukupni etilni esteri n-3 kiselina su >90, ili
d) etilni ester DHA je >80, a etilni ester EPA je <15, gdje etilni esteri EPA + DHA su >85,
u pripravi lijeka za sprječavanje i/ili liječenje psihijatrijskih poremećaja središnjeg živčanog sustava (CNS), koje se bira između shizofrenije, manično-depresivnog sindroma, velike depresije, te Alzheimerove bolesti.
2. Upotreba u skladu s patentnim zahtjevom 1, gdje shizofrenija pokazuje negativne i/ili pozitivne simptome.
3. Upotreba u skladu s patentnim zahtjevom 1 ili 2, gdje shizofrenija je paranoidna, katatonična, dezorganizirana ili nediferencirana shizofrenija.
4. Upotreba u skladu s patentnim zahtjevom 1, gdje manično-depresivni sindrom i velika depresija uključuju poremećaje raspoloženja, ponašanja i autonomnih funkcija, povezanih s aktivnošću, spavanjem i tekom.
5. Upotreba u skladu s patentnim zahtjevom 1, gdje Alzheimerova bolest uključuje različite slične oblike demencije.
6. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje pripravak sadrži najmanje još jednu n-3 i/ili n-6 polinezasićenu i/ili mononezasićenu i/ili zasićenu masnu kiselinu.
7. Upotreba u skladu s prethodnim patentnim zahtjevom, gdje pripravak sadrži najmanje još dvije druge n-3 i/ili n-6 polinezasićene i/ili mononezasićene i/ili zasićene masne kiseline, u bilo kojem odnosu između njih.
8. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek se primjenjuje oralno.
9. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek je u obliku mekih želatinskih kapsula.
10. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek se primjenjuje u dozi od 0,1-5 g dnevno.
11. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek se primjenjuje u dozi od 0,3-3 g dnevno.
12. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek se primjenjuje u dozi od 1-2 g dnevno.
13. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek se primjenjuje odvojeno, kao suadjuvans ili pomoćni lijek, od najmanje još jednog lijeka djelotvornog u sprječavanju i/ili liječenju psihijatrijskih poremećaja CNS-a.
14. Upotreba u skladu s bilo kojim od prethodnih patentnih zahtjeva, gdje lijek sadrži najmanje još jedan lijek djelotvoran u sprječavanju i/ili liječenju psihijatrijskih poremećaja CNS-a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000069A ITMI20040069A1 (it) | 2004-01-21 | 2004-01-21 | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| PCT/EP2005/000522 WO2005070411A1 (en) | 2004-01-21 | 2005-01-20 | USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090550T1 true HRP20090550T1 (hr) | 2010-01-31 |
Family
ID=34803698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090550T HRP20090550T1 (hr) | 2004-01-21 | 2009-10-15 | UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8829048B2 (hr) |
| EP (1) | EP1706106B9 (hr) |
| JP (1) | JP5087280B2 (hr) |
| DE (1) | DE602005015415D1 (hr) |
| DK (1) | DK1706106T3 (hr) |
| ES (1) | ES2329809T3 (hr) |
| HR (1) | HRP20090550T1 (hr) |
| IT (1) | ITMI20040069A1 (hr) |
| PL (1) | PL1706106T3 (hr) |
| PT (1) | PT1706106E (hr) |
| RS (1) | RS51195B (hr) |
| WO (1) | WO2005070411A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| EP1772146A1 (en) * | 2005-10-03 | 2007-04-11 | Neuropharma, S.A. | Polyunsaturated fatty acids as bace inhibitors |
| EP1968567B1 (en) | 2005-12-20 | 2014-06-18 | Cenestra, Llc | Omega 3 fatty acid formulations |
| ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| AU2006327064B2 (en) | 2005-12-21 | 2012-04-26 | Brudy Technology, S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
| US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
| EP2612672A1 (en) | 2007-03-28 | 2013-07-10 | Aker BioMarine AS | Bioeffective krill oil compositions |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| CA2773031C (en) | 2008-09-09 | 2021-03-02 | Orygen Youth Health Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| AU2015203289B2 (en) * | 2008-09-09 | 2017-03-16 | Orygen Research Centre | Prevention of psychotic disorders and/or treatment of psychotic symptoms |
| US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
| WO2012083034A1 (en) * | 2010-12-15 | 2012-06-21 | Louis Sanfilippo | Modulation of neurotrophic factors by omega-3 fatty acid formulations |
| AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
| GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
| KR102079747B1 (ko) | 2015-02-11 | 2020-02-20 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 조성물 |
| PT3256003T (pt) | 2015-02-11 | 2023-02-15 | Aker Biomarine Antarctic As | Processo de extração de lipídios |
| EP3586640A1 (en) | 2018-06-21 | 2020-01-01 | Nuseed Pty Ltd | Dha enriched polyunsaturated fatty acid compositions |
| PL238670B1 (pl) * | 2018-07-06 | 2021-09-20 | Skotan Spolka Akcyjna | Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych |
| JPWO2022050355A1 (hr) * | 2020-09-04 | 2022-03-10 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1239587A (en) | 1983-10-24 | 1988-07-26 | David Rubin | Combined fatty acid composition for lowering blood cholestrol and triglyceride levels |
| GB8601915D0 (en) | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| IT1205043B (it) * | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
| DE3739700A1 (de) * | 1987-11-24 | 1989-06-08 | Guenther Dr Med Jeschke | Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin |
| JP2524217B2 (ja) | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| GB2218904A (en) | 1988-05-27 | 1989-11-29 | Renafield Limited | Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid |
| GB2218984B (en) | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| FR2688145B1 (fr) | 1992-03-06 | 1994-09-23 | Borden France Sa | Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur. |
| JPH0672868A (ja) * | 1992-08-26 | 1994-03-15 | Maruha Corp | 抗精神病薬 |
| GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| DE69720787T2 (de) * | 1996-10-11 | 2004-03-18 | Scarista Ltd., Douglas | Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
| DE60022987T2 (de) | 2000-05-22 | 2006-10-19 | Pro Aparts - Investimentos E Consultoria Lda., Funchal | Fettsäurezusammensetzung, die wenigstens 80 Gew.-% EPA und DHA enthält |
| IT1320180B1 (it) | 2000-12-29 | 2003-11-26 | Hunza Di Marazzita Maria Carme | Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e |
| US6759435B1 (en) * | 2003-07-03 | 2004-07-06 | A.P. Group Inc. | Antidepressant drugs and methods |
-
2004
- 2004-01-21 IT IT000069A patent/ITMI20040069A1/it unknown
-
2005
- 2005-01-20 WO PCT/EP2005/000522 patent/WO2005070411A1/en active Application Filing
- 2005-01-20 DE DE602005015415T patent/DE602005015415D1/de active Active
- 2005-01-20 PL PL05701068T patent/PL1706106T3/pl unknown
- 2005-01-20 US US10/586,863 patent/US8829048B2/en not_active Expired - Fee Related
- 2005-01-20 JP JP2006550032A patent/JP5087280B2/ja not_active Expired - Fee Related
- 2005-01-20 RS RSP-2009/0437A patent/RS51195B/sr unknown
- 2005-01-20 ES ES05701068T patent/ES2329809T3/es active Active
- 2005-01-20 DK DK05701068T patent/DK1706106T3/da active
- 2005-01-20 EP EP05701068A patent/EP1706106B9/en not_active Revoked
- 2005-01-20 PT PT05701068T patent/PT1706106E/pt unknown
-
2009
- 2009-10-15 HR HR20090550T patent/HRP20090550T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2329809T3 (es) | 2009-12-01 |
| PL1706106T3 (pl) | 2009-12-31 |
| JP2007518764A (ja) | 2007-07-12 |
| DE602005015415D1 (de) | 2009-08-27 |
| US20070161705A1 (en) | 2007-07-12 |
| EP1706106A1 (en) | 2006-10-04 |
| EP1706106B9 (en) | 2009-09-16 |
| RS51195B (sr) | 2010-10-31 |
| DK1706106T3 (da) | 2009-10-12 |
| PT1706106E (pt) | 2009-09-04 |
| US8829048B2 (en) | 2014-09-09 |
| EP1706106B1 (en) | 2009-07-15 |
| JP5087280B2 (ja) | 2012-12-05 |
| ITMI20040069A1 (it) | 2004-04-21 |
| WO2005070411A1 (en) | 2005-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090550T1 (hr) | UPOTREBA VISOKO KONCENTRIRANIH PRIPRAVAKA ODABRANIH n-3 MASNIH KISELINA U LIJEČENJU POREMEĆAJA SREDIŠNJEG ŽIVČANOG SUSTAVA | |
| JP2007518764A5 (hr) | ||
| FR2860976B1 (fr) | Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral. | |
| DK1157692T3 (da) | Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf | |
| JP2015143248A5 (hr) | ||
| DK1310249T3 (da) | Anvendelse af polyumættede fedtsyrer til primær forebyggelse af större hjerte-kar anfald | |
| DE60203494D1 (de) | Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen | |
| RU2001121185A (ru) | Этил-ЭПК с высокой степенью чистоты и другие производные ЭПК для психиатрических и неврологических расстройств | |
| NO20076382L (no) | Anvendelse av dokosaheksaenglyserider i behandlingen av tumorese sykdommer | |
| JP7335475B2 (ja) | 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物 | |
| RU2002133098A (ru) | Терапевтические комбинации жирных кислот | |
| FR2878747B1 (fr) | Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih | |
| HRP20200394T1 (hr) | Smjesa masnih kiselina (gmk, grupa masnih kiselina) za primjenu u liječenju inflamatornih patologija | |
| JP2015500639A5 (hr) | ||
| WO2012049227A3 (en) | Novel omega-3 and omega-6 fatty acid compositions and uses thereof | |
| JP2008540484A5 (hr) | ||
| BR0306655A (pt) | Genes elongase e usos dos mesmos | |
| JP2017523230A5 (hr) | ||
| JP5043677B2 (ja) | アルツハイマー型認知症予防・治療剤 | |
| MX2015007085A (es) | Composiciones de acido omega-3 pentanoico y metodos de uso. | |
| JP2016501248A5 (hr) | ||
| RS20070367A (en) | A synergistically heat stable oil media having eicosa pentanoic acid (epa) and docosa hexanoic acid (dha) | |
| JP2008531675A5 (hr) | ||
| Suresh | EFFECT OF OMEGA-3 FATTY ACID ON LEAD MALE WISTAR RATS | |
| JP2017522278A5 (hr) |